Recursion Pharmaceuticals RXRX
NASDAQ RXRX
$3.70 +0.12 (+3.35%)
At close: Oct 23, 2026 · 4:00 PM EDT

Recursion Pharmaceuticals (RXRX) Sale and Maturity of Investments (2021 - 2022)

Updated

Analysis

Recursion Pharmaceuticals (RXRX) Sale and Maturity of Investments (2021 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn -
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 308.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 1.30 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 136.00 Mn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn -
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.03 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 2.12 Bn
10 Recursion Pharmaceuticals 1.98 Bn -627.04 Mn -3.82 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 61.55 Mn
Jun 30, 2022 21.42 Mn
Mar 31, 2022 147.65 Mn
Dec 31, 2021 69.19 Mn
API Access

Recursion Pharmaceuticals Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=RXRX&period=max&api_key=YOUR_API_KEY